165 related articles for article (PubMed ID: 36032036)
21. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
[TBL] [Abstract][Full Text] [Related]
23. Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution.
Li X; Zhao LJ; Liu NB; Zhang WC; Pang QS; Wang P; Yuan ZY
Asian Pac J Cancer Prev; 2015; 16(4):1463-9. PubMed ID: 25743816
[TBL] [Abstract][Full Text] [Related]
24. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
25. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
[No Abstract] [Full Text] [Related]
26. Comparison of involved-field intensity-modulated radiotherapy combined with S-1
Liu LH; Yan MH; Di YP; Fu ZG; Zhang XD; Li HQ
World J Clin Cases; 2022 Jul; 10(21):7365-7375. PubMed ID: 36157997
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy.
Du XX; Yu R; Wang ZF; Du DC; Liu QY; Wang RM; Kang SR; Yang H
Bosn J Basic Med Sci; 2019 May; 19(2):186-194. PubMed ID: 30877837
[TBL] [Abstract][Full Text] [Related]
28. Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma.
Tan L; Xiao Z; Zhang H; Chen D; Feng Q; Zhou Z; Lv J; Liang J; Yin W
Cancer Radiother; 2020 Feb; 24(1):21-27. PubMed ID: 32001131
[TBL] [Abstract][Full Text] [Related]
29. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer.
Jing Z; Chen T; Zhang X; Wu S
Cancer Sci; 2017 Sep; 108(9):1828-1833. PubMed ID: 28665042
[TBL] [Abstract][Full Text] [Related]
31. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].
Hu MM; Yuan QQ; Zhang XS; Yang S; Wang X; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Pang QS; Zhao YD; Sun XC; Li GF; Li L; Qiao XY; Liu ML; Wang YD; Li C; Zhu SC; Han C; Zhang KX; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):676-681. PubMed ID: 32867461
[No Abstract] [Full Text] [Related]
33. Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II-III Esophageal Squamous Cell Carcinoma.
Zhu H; Lu X; Jiang J; Lu J; Sun X; Zuo Y
Dose Response; 2022; 20(1):15593258221076720. PubMed ID: 35273471
[TBL] [Abstract][Full Text] [Related]
34. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.
Li C; Wang X; Wang L; Chen J; Zhang W; Pang Q; Zhao Y; Sun X; Zhang K; Li G; Li L; Qiao X; Liu M; Wang Y; Deng L; Wang W; Bi N; Zhang T; Deng W; Ni W; Chang X; Han W; Zhou Z; Liang J; Feng Q; Wang L; Chen D; Lv J; Zhu S; Han C; Xiao Z
Acta Oncol; 2021 May; 60(5):627-634. PubMed ID: 33793382
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
36. Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis.
Gao Q; Liu ZY; Cheng Y; Di XK; Zhang YM; Sun XC; Xia XJ; Ge XL
Cancer Radiother; 2022 Nov; 26(8):1002-1007. PubMed ID: 35933288
[TBL] [Abstract][Full Text] [Related]
37. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study.
Fan XW; Wang HB; Mao JF; Li L; Wu KL
Cancer Med; 2020 Apr; 9(8):2812-2819. PubMed ID: 32100452
[TBL] [Abstract][Full Text] [Related]
38. Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China.
Lyu J; Yisikandaer A; Li T; Zhang X; Wang X; Tian Z; Chen L; Lu B; Chen H; Yang J; Wang Q; Zhang J; Ma Y; Liu R; Liu R; Hage A; Lang J
Cancer Med; 2020 Oct; 9(20):7460-7468. PubMed ID: 32841543
[TBL] [Abstract][Full Text] [Related]
39. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
40. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
